Although the exogenous growth factors bFGF, EGF, and HGF have been found to not affect V600E-BRAF melanoma viability or response to BRAF-inhibitors [60], we have previously reported that GHR inhibition sensitizes human melanoma to the BRAF inhibitor vemurafenib by suppressing ABC-transporter-mediated clearance of vemurafenib [21]. Here, BRAF is linked to melanoma.